Proactive Strategies for Mpox Vaccine Implementation: Bridging Theory and Practice
-
By
-
Sung-mok Jung
-
Fuminari Miura
-
Hiroaki Murayama
-
Sebastian Funk
-
Jacco Wallinga
-
Justin Lessler
-
Akira Endo
-
July 21, 2025
Clinical Scorecard: Proactive Strategies for Mpox Vaccine Implementation: Bridging Theory and Practice
At a Glance
| Category | Detail |
|---|
| Condition | Mpox (Monkeypox) infection, clade IIb and clade I |
| Key Mechanisms | Rapid infection spread in heterogeneous sexual networks; infection-acquired immunity in core groups; narrow time window for effective vaccination |
| Target Population | High-risk groups, particularly men who have sex with men with high numbers of sexual partners; broader populations in clade I outbreaks |
| Care Setting | Public health vaccination programs in outbreak and preemptive contexts |
Key Highlights
- Timing of vaccine deployment is critical due to rapid saturation of infection-acquired immunity in core groups.
- Reactive vaccination often occurs after sustained transmission, limiting population-level impact despite individual protection.
- Preemptive vaccination strategies face challenges including early detection, political dilemmas, and logistical constraints.
Guideline-Based Recommendations
Diagnosis
- Enhance timely case detection to identify early transmission signals.
- Address structural barriers such as social stigma and limited diagnostic capacity.
Management
- Implement intensive vaccination targeting high-risk populations promptly.
- Tailor vaccination timing and targets to local epidemiologic and social contexts, considering clade-specific transmission patterns.
Monitoring & Follow-up
- Use real-time importation risk modeling to inform early-warning and vaccination decisions.
- Maintain surveillance systems for timely outbreak information sharing.
Risks
- Delayed vaccine deployment reduces population-level impact and herd immunity potential.
- Political and operational challenges may delay preemptive vaccination.
- Risk of overreaction when initiating vaccination without confirmed local transmission.
Patient & Prescribing Data
High-risk individuals during clade IIb outbreaks; broader populations in clade I outbreaks
Vaccines demonstrate 66%–85% effectiveness against disease; delayed administration limits indirect protection benefits.
Clinical Best Practices
- Prioritize early and proactive vaccination in high-risk groups to interrupt transmission.
- Invest in resilient infrastructure and public trust to support vaccination efforts.
- Coordinate globally to ensure equitable vaccine access and timely outbreak information sharing.
- Adapt immunization strategies to local transmission dynamics and clade differences.
References
